Abstract
Introduction
With Avastin as its bright star, the therapeutic field of anti-angiogenic and
vascular targeting drugs in oncology is becoming re-energized. While
fragmentation of the oncology market is set to occur as treatment becomes
based on tumor growth drivers rather than primary tumor site, the use of
targeted therapies, such as anti-angiogenesis, will occur in combination with
traditional cytotoxic chemotherapy agents.
Scope of this report
- In-depth competitive landscape assessment of the anti-angiogenesis market
in oncology
- Thorough review of utilized targets in anti-angiogenic and vascular target
drug development
- Thorough review of approved drugs
- Progress analysis of five major cancer indications, including players,
drugs, clinical progress and pitfalls
Research and analysis highlights
- Companies with the ten highest numbers of clinical trials make up more
than 40% of all research and development done in anti-angiogenesis and
vascular targeting in onoclogy, but they just constitute 10% of the
competitors in the field.
- More than 100 anti-angiogenic drugs have been described with one or more
targets. These 75 drug targets are a mixture of weaker and stronger targets in
angiogenesis.
- The prostate cancer market is reaching maturity, and major players' sales
have been eroded by the launch of various LHRH agonist depot formulations,
BioSeeker identifies that angiogenesis inhibitors will be the most promising
for future treatment of prostate cancer.
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization
of anti-angiogenic and vascular targeting drugs
- Assess opportunities and risks for the continued development of
anti-angiogenic and vascular targeting agents in five major cancer indications.
- Adopt knowledge from this analysis to drive strategic planning decisions
in oncology drug development
Some of the almost 100 drugs included in this analysis
2-methoxyestradiol, AMG-706, ATN-161, AZD-2171, bevacizumab, combretastatin
A-4 prodrug, enzastaurin hydrochloride, everolimus, neovastat, PTK/ZK,
sorafenib tosylate, squalamine, thalidomide, vitaxin, XL-999, ZD-6474,
volociximab etc.
Some of the more than 100 companies included in this analysis
Adherex, Aeterna Zentaris, Amgen, AstraZeneca, Bayer, Celgene, Chugai, Eli
Lilly, EntreMed, Eisai, Exelixis, Genaera, Genentech, Hoffmann-La Roche, Merck
KGaA, Novartis, OXiGENE, PDL BioPharma, PharmaMar, Wilex etc.
| 
View Cart
